The Company also announced that the lead investigator for the constipation-predominant irritable bowel syndrome program, Mark Pimentel, MD, has joined Synthetic Biologics as chairman of the clinical advisory board.
Dr. Pimentel is director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai Medical Center in Los Angeles.
Synthetic Biologics is a developer of anti-infective biologic and drug candidates targeting specific pathogens.
More Articles on Gastroenterology:
9 Statistics on Gastroenterologist Compensation by Location
AGA Calls for More Transparency From CMS
The Growing Role of Biologics in Gastroenterology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
